Navigation Links
Symmetry Medical Expands Board of Directors
Date:1/8/2008

WARSAW, Ind., Jan. 8 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), an independent provider of products to the global orthopedic device industry and other medical markets, announced today that the board of directors has voted to expand the size of the Company's board from five to seven. It has appointed two new independent directors, John S. Krelle and Craig B. Reynolds to fill the positions, bringing the total of independent directors to six.

Mr. Krelle is President, Chief Executive Officer and a member of the board of directors of FzioMed, Inc., a privately held medical biomaterials company based in San Luis Obispo, California. FzioMed's technology is being used in spine/orthopedic surgery, general surgery and aesthetic surgery. Prior to FzioMed, Mr. Krelle spent nearly twenty years in a variety of senior international positions at Zimmer Holdings, Inc., including President of Asian based operations in Japan. Mr. Krelle was educated in the United Kingdom and holds a degree in mechanical engineering and a Masters of Business Administration.

Mr. Reynolds is Chief Operating Officer and a member of the board of directors of Respironics, Inc., a publicly held company that develops, manufactures and markets medical devices worldwide. Its product lines include sleep medicine therapeutics and diagnostic equipment, intensive care ventilation and patient monitoring and respiratory drug delivery systems. From 1981 to 1998, Mr. Reynolds was at Healthdyne Inc., a medical device company, serving for five years as Chief Executive Officer and board member. Mr. Reynolds holds a degree in industrial management and a Masters of Business Administration.

Frank Turner, Chairman of the Symmetry board, said, "We are pleased to welcome John and Craig to the Symmetry board. These two individuals have strong backgrounds in the healthcare industry and proven track records of success. Their global healthcare industry experience and worldwide market knowledge will be invaluable as we continue to diversify outside of our core orthopedic business and develop our presence in new international markets."

Brian Moore, President and Chief Executive Officer of Symmetry Medical, said, "The increased size of our board is most welcome and should provide more valuable input to meet the growing requirements of our business. We particularly look forward to working with John and Craig as they bring direct relevant industry experience and considerable international operational knowledge, particularly in Asia, which will be most useful to strengthen and develop our global strategy."

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Forward-Looking Statements

Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual results could differ materially from our current expectations. Certain factors that could cause actual results to differ include: the loss of one or more customers; the development of new products or product innovations by our competitors; product liability; changes in management; changes in conditions effecting the economy, orthopedic device manufacturers or the medical device industry generally; and changes in government regulation of medical devices and third-party reimbursement practices. We refer you to the "Risk Factors" and "Forward Looking Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at http://www.sec.gov.

Investors/Media: Contact:

The Ruth Group Symmetry Medical Inc.

Nick Laudico/Jason Rando Fred L. Hite

(646) 536-7030/7025 Senior Vice President

nlaudico@theruthgroup.com Chief Financial Officer

jrando@theruthgroup.com (574) 371-2218


'/>"/>
SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
2. Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7, 2007
3. Symmetry Medical Reports Preliminary Third Quarter Revenue
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. BioMS Medical announces its intention to renew a normal course issuer bid
9. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
10. ATS Medical Expands Open Pivot Heart Valve Offerings
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today announced ... the sale of 12,835,490 shares of its common stock ... of companies. In connection with the sale of its common ... cash and issue to GlobeImmune 200,000 shares, an estimated ... "We are pleased to enter into this ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):